Alzheimer’s Blood Tests: Uses, Limits and Diagnosis

Blood biomarker tests can help clinicians assess whether amyloid changes associated with Alzheimer’s disease may be present. They do not diagnose Alzheimer’s disease on their own, are not intended for general population screening and cannot explain every cause of memory or thinking problems.

A proper assessment considers symptoms, medical history, medicines, daily functioning, cognitive testing and other possible causes. Depending on the person, it may also include physical examination, laboratory tests, brain imaging or specialist investigations.

What an Alzheimer’s blood biomarker test measures

Some tests measure forms of phosphorylated tau and amyloid-beta in plasma. The pattern or ratio is used to estimate whether amyloid pathology is likely. Amyloid pathology can support an Alzheimer’s assessment, but a biomarker result must be interpreted alongside clinical information.

In May 2025, the US Food and Drug Administration cleared a plasma-ratio test to aid assessment in people aged 55 or older who have signs and symptoms of cognitive decline in a specialist-care setting. FDA clearance is not permission to use the test as a symptom-free screening tool, and it does not make the result a stand-alone diagnosis.

Why the result is not a diagnosis

• A positive result can occur when Alzheimer’s disease is not the cause of the person’s symptoms.
• A negative result can occur despite relevant disease.
• Some results are indeterminate and require further assessment.
• Amyloid changes can coexist with other neurological or medical conditions.
• The test does not predict an individual’s rate of progression.

The FDA describes false-positive and false-negative results as important risks. It also says results must be considered with other clinical information. Certain lots of one cleared assay were subject to a 2026 Class II recall because inaccurate results could occur; clinicians and laboratories should check current product and lot information rather than relying on an older article.

How memory problems are assessed

Memory difficulty does not always mean dementia. Depression, anxiety, sleep problems, infection, thyroid disease, vitamin deficiency, medicine effects, alcohol, hearing or vision problems and other conditions can affect thinking. Some causes may be treatable.

A clinician may ask when symptoms began, whether they are changing and how they affect everyday activities. With permission, information from someone who knows the person well can be helpful. Cognitive tests are only one part of the assessment. Routine blood tests are commonly used to look for other causes; these are different from a blood biomarker test intended to assess Alzheimer’s pathology.

Who may be considered for biomarker testing

Testing may be considered when a person has cognitive symptoms and the result would help a qualified clinician decide on further assessment or management. Availability, regulatory status and clinical pathways differ between countries and can change.

Testing people without symptoms can produce difficult or misleading results and is not the intended use of the FDA-cleared plasma test discussed here. Online or direct-to-consumer offers should not replace a memory assessment.

Questions to ask before testing

• Why is this test appropriate for my symptoms and age?
• Is the specific assay authorised for this intended use in the country where it will be performed?
• Which laboratory will perform it, and has the clinician checked current safety notices or recalls?
• What can a positive, negative or indeterminate result mean?
• Which additional assessments may still be needed?
• How will the result affect care, and who will explain it?
• What are the total costs and follow-up arrangements in writing?

Treatment decisions require specialist review

A biomarker result should not be used by itself to start or stop medicine. Eligibility for disease-modifying treatment involves diagnosis, disease stage, imaging, other health conditions, medicines, potential adverse effects and monitoring requirements. A specialist should discuss potential benefits, uncertainties and risks with the person and, where appropriate, their family or carer.

Revitalize provider clarification

This general guide does not state that Revitalize, its contracted doctors or hospitals provide Alzheimer’s blood biomarker testing, dementia diagnosis or disease-modifying treatment. No specialist service should be inferred from a general provider directory.

If Revitalize is asked to coordinate an assessment, the named clinician, contracted facility, exact test, regulatory status, scope of care, total cost and follow-up plan must be confirmed in writing before travel. General Revitalize doctor information and contracted hospital information do not establish dementia-specialist capability.

When to seek help

Arrange a local medical assessment when memory or thinking changes affect daily life or are getting worse. Sudden confusion, new weakness, facial droop, speech difficulty, severe headache, seizure, loss of consciousness or an immediate safety concern needs urgent local care. International travel should not delay emergency assessment.

Independent guidance

For current regulatory detail, read the FDA notice about the first cleared Alzheimer’s blood test and check the FDA recall database for the exact product and lot. The NHS explains how Alzheimer’s disease is diagnosed. NICE provides guidance on dementia assessment, diagnosis and support.

This article is general information and does not replace individual medical advice, diagnosis or emergency care. Regulatory status, availability and safety notices can change.